Status:

RECRUITING

Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke

Lead Sponsor:

Assiut University

Conditions:

Acute Ischemic Stroke

Acute Haemorrhagic Stroke

Eligibility:

All Genders

18-80 years

Brief Summary

Searching electrical activity registered by EEG in acute ischemic and hemorrhagic stroke and comparing these parameters to the poststroke recovery patterns to investigate the role of EEG as a differen...

Detailed Description

In this study, EEG will be performed on each patient included; within 72 hours of the onset of the stroke. The EEG device will be used within the intended use as described in the user manuals. The ele...

Eligibility Criteria

Inclusion

  • Age above 18 and below 80 years.
  • Acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI.
  • Acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT.
  • Stroke onset \<72 hours before expected time of performing EEG.
  • First-ever ischemic stroke.
  • Measurable deficit on the National Institute of Health Stroke Scale (NIHSS).
  • Able to give and sign informed consent.

Exclusion

  • Transient Ischemic Attacks (TIAs).
  • Greater than 72 hours past the initial insult.
  • Patients with subarachnoid haemorrhage, traumatic haemorrhage (epidural/subdural bleeding), cerebral venous sinus thrombosis, indication for urgent neurosurgical intervention.
  • History of other central nervous system diseases.
  • Any signs unfit for MRI/EEG scan.
  • Injury or active infection of electrode cap placement area.
  • Claustrophobia; recognition disorder.
  • Known skull defect or head trauma.
  • Previous neurological procedure (metallic implant, brain pace, cranial operation history).
  • Significant physical impairment that would restrict the ability to use the portable EEG devices.
  • Presence of malignancy or systemic rheumatic disease
  • Non-stroke disease or lesion affecting the sensorimotor system.
  • Alcohol or drug addiction.
  • Presence of pump/shunt.
  • Presence of Malignancy.
  • Presence of severe cognitive impairment.
  • History of epilepsy or taking medication due to epilepsy.

Key Trial Info

Start Date :

June 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06984965

Start Date

June 1 2025

End Date

June 1 2026

Last Update

May 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Neurology Department, Faculty of Medicine, Assiut University

Asyut, Asyut Governorate, Egypt, 71511